EUVIMEDEUVIMED entdecken
Crossref

BRAF ‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy

Chan-Juan Wang iD, Ting Zhu, Chen-Zi Zhao, Hua Cui, Dong Wang, Zi-Jing Zhao, Xiao-Tong Huang, Hua-Lin Li, Fei-Fei Liu, Rui Zhang iD, Zhi-Gang Li iD, Lei Cui

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Chan-Juan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for C…. Hauptthemen laut MEDLINE: Histiocytosis, Langerhans-Cell, Proto-Oncogene Proteins B-raf, Leukocytes, Mononuclear, Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Capital's Funds for Health Improvement and Research, Beijing Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical relevance of BRAF ‐V600E alleles in peripheral blood mononuclear cells (PBMCs) and the prognostic impact of the mutants in cell‐free (cf) and PBMC DNAs of Langerhans cell histiocytosis (LCH) have not been fully clarified in pediatric LCH.

Methods

We retrospectively determined the levels of BRAF ‐V600E mutation in paired plasma and PBMC samples at the time of diagnosis of LCH. Subsequently, we performed a separate or combined analysis of the clinical and prognostic impact of the mutants.

Results

We assessed B RAF‐ V600E mutation in peripheral blood from 94 patients of childhood LCH. Our data showed that cf BRAF ‐V600E was related to young age, multiple‐system (MS) disease, involvements of organs with high risk, increased risk of relapse, and worse progression‐free survival (PFS) of patients. We also observed that the presence of BRAF ‐V600E in PBMCs at baseline was significantly associated with MS LCH with risk organ involvement, younger age, and disease progression or relapse. The coexisting of plasma (+) /PBMC (+) identified 36.2% of the patients with the worst outcome, and the hazard ratio was more significant than either of the two alone or neither, indicating that combined analysis of the mutation in plasma and PBMCs was more accurate to predict relapse than evaluation of either one.

Conclusions

Concurrent assessment of BRAF ‐V600E mutation in plasma and PBMCs significantly impacted the prognosis of children with LCH. Further prospective studies with larger cohorts need to validate the results of this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histiocytosis, Langerhans-CellProto-Oncogene Proteins B-rafLeukocytes, MononuclearMutationHumansMaleFemaleRetrospective StudiesChildChild, PreschoolPrognosisInfantAdolescentFollow-Up StudiesSurvival Rate

Stichwörter der Autor:innen

BRAF‐V600ELangerhans cell histiocytosiscell‐free DNAperipheral blood mononuclear cellsprognostic factors

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Hematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Beijing Key Laboratory of Pediatric Hematology-Oncology, Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • National Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
  • Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.

ORCID-Profile: Chan-Juan Wang, Rui Zhang, Zhi-Gang Li

Förderung

  • Capital's Funds for Health Improvement and Research
  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China
  • Funding for Reform and Development of Beijing Municipal Health Commission
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Wang, C. J., Zhu, T., Zhao, C. Z., Cui, H., Wang, D., Zhao, Z. J., Huang, X. T., Li, H. L., Liu, F. F., Zhang, R., Li, Z. G., & Cui, L. (2024). BRAF ‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31099

Vancouver

Wang CJ, Zhu T, Zhao CZ, Cui H, Wang D, Zhao ZJ, et al. BRAF ‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31099

BibTeX
@article{Wang2024,
  author = {Wang, Chan-Juan and Zhu, Ting and Zhao, Chen-Zi and Cui, Hua and Wang, Dong and Zhao, Zi-Jing and Huang, Xiao-Tong and Li, Hua-Lin and Liu, Fei-Fei and Zhang, Rui and Li, Zhi-Gang and Cui, Lei},
  title = {BRAF ‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31099}
}
Kostenlos starten →